Knowthestock.com
CPHI - China Pharma Holdings Inc.
Compare

Sell

Weak Growth●Earnings/Profit is Negative

14%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -0.53%
Operating Income is Negative but improving
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -26.38%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 0.47
Debt Ratio is 0.62
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.34
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
China Pharma Holdings Inc. (CPHI) - http://www.chinapharmaholdings.com
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnique Co., Ltd., is located in Haikou City, Hainan Province.
Exchange - NYSE MKT LLC
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Zhilin Li
    Close
Cookie Policy
Disclaimer
Privacy Policy
Terms of Service
About Us
Contact Us
Help
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.